Table 3.

The eight drug candidates identified by multiple omics analysis in this study.

Name	Activity	Disease	ATC	KEGG DGroup
Estradiol	Menstruation disorder agent, Estrogen receptor agonist	Postmenopausal osteoporosis	Genito urinary system and sex hormones (G)	Other, Cyp substrate
Etoposide	Antineoplastic, Topoisomerase II inhibitor	Testicular tumors, Small cell lung cancer	Antineoplastic and immunomodulating agents (L)	Other, Cyp substrate
Resveratrol	Antiinflammatory agents	Herpes labialis infections
Simvastatin	Antihyperlipidemic, HMG-CoA reductase inhibitor	Hyperlipidemia, Heterozygous familial hypercholesterolemia	Cardiovascular system (C)	Cardiovascular agent, Cyp substrate
Sirolimus	Antineoplastic, Immunosuppressant, mTOR inhibitor	Lymphangioleiomyomatosis	Antineoplastic and immunomodulating agents (L), Sensory organs (S)	Antineoplastic, Transporter substrate
Valproic acid	Anticonvulsant	Seizure disorders, Migraine headache.	Nervous system (N)	Neuropsychiatric agent, Other, Cyp substrate
Vorinostat	Antineoplastic, Histone deacetylase inhibitor	Cutaneous T-cell lymphoma	Antineoplastic and immunomodulating agents (L)
Y-27632	ROCK family kinase inhibitor, hiPS/ES Cell death inhibitor